Verona Pharma plc (VRNA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in London, United Kingdom. The current CEO is David S. Zaccardelli.
VRNA has IPO date of 2017-04-28, 209 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $72.68B.
Verona Pharma plc is a clinical-stage biopharmaceutical company headquartered in London, focused on developing innovative therapies for respiratory diseases with significant unmet medical needs. The company's lead product candidate is ensifentrine, an inhaled dual inhibitor of phosphodiesterase 3 and 4 enzymes that functions as both a bronchodilator and anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis, with development proceeding across three delivery formulations: nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Founded in 2005, Verona Pharma is advancing a potentially transformative approach to respiratory disease management.
